Abstract
References
l. Halsey JP. The introduction of a bone densitometry service. Lancaster & Westmorland Medical Journal 1992;1(8):209-12. Available from: https://doi.org/10.48037/mbmj.v1i8.1180
Department of Health. National Service Framework for Older People. Department of Health; 2001.
National Institute for Clinical Excellence. Bisphosphonates, selective oestrogen receptor modulator and parathyroid hormone for the secondary prevention of osteoporotic fragility fracture in postmenopausal women. Technology appraisal 87. 2005
Barr RJ, Adebajo A, Fraser WD, et al. Can peripheral DXA measurements be used to predict fractures in elderly women living in the community? Osteoporos Int 2005;15:937-41. Available from: https://doi.org/10.1007/s00198-005-1836-1
Lips P. Vitamin D deficiency and secondary hyperparathyroidism in the elderly: consequences for bone loss and fractures and therapeutic implications. Endocr Rev 2001;22:477-501. Available from: https://doi.org/10.1210/edrv.22.4.0437
Van Pottelbergh I, Goemaere S, Zmierczak H , Kaufman JM. Perturbed sex steroid status in men with idiopathic osteoporosis and their sons. J Clin Endocrinal Metab 2004·89(10):4949-53. Available from: https://doi.org/10.1210/jc.2003-032081
Gamero P, Sornay-Rendu E, Duboeuf F, Delma PD. Marker of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study. J Bone Miner Res 1999:14(9):1614-21. Available from: https://doi.org/10.1359/jbmr.1999.14.9.1614
Black DM, Cummings SR, Karpf DB, et al . Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996;348(9041):1535-41. Available from: https://doi.org/10.1016/s0140-6736(96)07088-2
Bjarnson NH, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001;12(11):922-30. Available from: https://doi.org/10.1007/s001980170020
Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 2003;18(6):1051-6. Available from: https://doi.org/10.1359/jbmr.2003.18.6.1051
Porthouse J, Cockayne S, King C, et al. Randomised controlled trial of calcium and supplementation with cholecalciferol (vitamin D3) for prevention of fractures in primary care. Br Med J 2005;330(7498):1003. Available from: https://doi.org/10.1136/bmj.330.7498.1003
Grant AM, Avenell A, Campbell MK, et al. The RECORD trial group. Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people: a randomised placebo controlled trial. Lancet 2005;365(9471):1621-8. Available from: https://doi.org/10.1016/S0140-6736(05)63013-9
Rossouw JE, Anderson GL, Prentice RL, et al . Risks and benefit of estrogen plus progestin in healthy postmenopausal women: principal results. From the Women' Health Initiative randomised controlled trial. JAMA 2002;288:321-33. Available from: https://doi.org/10.1001/jama.288.3.321
Physiotherapy Guidelines for the management of osteoporosis. Chartered Society of Physiotherapy, March 1999
Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994;331(13):821-7. Available from: https://doi.org/10.1056/NEJM199409293311301